A 42-year-old woman from Mumbai with a history of myasthenia gravis presents with acute exacerbation of symptoms: ptosis, diplopia, and generalized muscle weakness. She was empirically started on ciprofloxacin 500 mg twice daily 2 days ago for a suspected respiratory tract infection. Her symptoms have worsened significantly since starting the antibiotic. Neurological examination confirms worsening of ocular and bulbar signs. What is the mechanism by which this fluoroquinolone is likely exacerbating her myasthenia gravis?

Explanation

## Fluoroquinolone-Induced Myasthenia Gravis Exacerbation ### Clinical Scenario This patient with known myasthenia gravis (MG) experienced acute worsening of neuromuscular symptoms within 48 hours of starting ciprofloxacin. The temporal relationship and absence of other precipitants (infection severity, medication non-compliance, or concurrent illness) point to a drug-induced exacerbation. ### Mechanism of FQ-Induced NMJ Dysfunction **Key Point:** Fluoroquinolones inhibit voltage-gated calcium channels at the presynaptic terminal of the neuromuscular junction, reducing the influx of Ca²⁺ ions and thereby decreasing acetylcholine (ACh) release. **High-Yield:** The mechanism is distinct from anticholinesterase inhibitors: - **FQs**: ↓ ACh *release* (presynaptic) → worsens MG - **Anticholinesterases** (e.g., pyridostigmine): ↑ ACh *availability* (postsynaptic) → helps MG In MG, the neuromuscular junction is already compromised due to antibodies against nicotinic ACh receptors. Reducing ACh release further tips the balance toward neuromuscular transmission failure. ### Pathophysiology in MG ```mermaid flowchart TD A[Normal NMJ]:::outcome --> B[ACh release from presynaptic terminal] B --> C[ACh binds to nicotinic receptors] C --> D[Depolarization & muscle contraction] E[Myasthenia Gravis]:::outcome --> F[Antibodies against ACh receptors] F --> G[Reduced functional ACh receptors] G --> H[Impaired neuromuscular transmission] I[+ Fluoroquinolone]:::urgent --> J[Inhibition of presynaptic Ca²⁺ channels] J --> K[↓ ACh release] K --> L[Further reduction in functional transmission] L --> M[Clinical exacerbation of MG]:::urgent ``` ### Fluoroquinolones and Neuromuscular Junction | Feature | Effect | Clinical Consequence | |---------|--------|---------------------| | Presynaptic Ca²⁺ channel inhibition | ↓ ACh release | Worsening of MG symptoms | | Postsynaptic receptor binding | Minimal direct effect | Not primary mechanism | | Anticholinesterase interaction | Displacement (minor) | Not the main problem | | Thymic function | No direct suppression | Not relevant | ### Clinical Pearl Fluoroquinolones are **contraindicated or used with extreme caution** in patients with myasthenia gravis. Other antibiotics with similar NMJ effects include: - Aminoglycosides (most notorious) - Macrolides (moderate risk) - Tetracyclines (lower risk) - β-lactams (safe) ### Management 1. **Discontinue ciprofloxacin immediately** 2. Switch to a safer antibiotic (e.g., amoxicillin-clavulanate, cephalosporin) 3. Optimize anticholinesterase therapy (increase pyridostigmine dose if needed) 4. Monitor for respiratory compromise; consider ICU admission if bulbar/respiratory involvement 5. Consider plasma exchange or IVIG if exacerbation is severe ### Mnemonic: "FQ NMJ Toxicity — CALCIUM BLOCK" - **CA**lcium channel inhibition (presynaptic) - **L**owered ACh release - **C**ompromised neuromuscular transmission - **I**ncreased risk in MG patients - **U**se alternative antibiotics - **M**onitor closely if unavoidable **BLOCK** = Presynaptic blockade of Ca²⁺-dependent ACh release [cite:KD Tripathi 8e Ch 49; Harrison 21e Ch 382]